Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddys gets CDSCO...

    Dr Reddys gets CDSCO Committee recommendation for approval for additional indications of Desosumab

    Farhat NasimWritten by Farhat Nasim Published On 2019-10-26T14:38:46+05:30  |  Updated On 16 Aug 2021 11:25 AM IST

    Recently, the Hyderabad-based Dr Reddy's Labs presented its proposal before the CDSCO Committee for an additional indication for Denosumab 120 mg/1.7ml (70 mg/ml) solution for injection and received a recommendation for approval of additional indications of the drug.


    New Delhi: Drug major, Dr Reddy's Laboratories (Dr Reddys) recently received a recommendation from the Subject Experts Committee of Central Drug Standard Control Organisation(CDSCO) for approval of additional indications for Desosumab 70mg/mL (Xgeva).


    Xgeva is a Rank ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal-related events in patients with advanced malignancies involving bone. The Xgeva brand of denosumab is used to prevent bone fractures and other skeletal conditions in people with multiple myeloma, and in people with tumours that have spread to the bone. Xgeva is also used to treat high blood levels of calcium caused by cancer.


    In 2016, Dr Reddy's had expanded its strategic collaboration with the US-based independent biotechnology firm Amgen to market and distribute in India three of latter's medicines, used in the therapy areas of oncology and osteoporosis. Under the terms of collaboration, Dr Reddy's was responsible for commercialising Xgeva (denosumab).


    Also Read: Dr Reddy Labs inks pact with Amgen to market three drugs in India


    Recently, the Hyderabad-based drugmaker presented its proposal before the CDSCO Committee for an additional indication for Denosumab 120 mg/1.7ml (70 mg/ml) solution for injection.


    After detailed deliberation, the CDSCO committee recommended for approval of the following indications:




    • Prevention of skeletal-related events in patients with multiple myeloma.

    • Treatment of giant cell tumour of bone in adults or skeletally mature adolescents


    CDSCO is the nodal regulatory head within which the Drug Controller General of India (DCGI) regulates pharmaceutical and medical devices, under the gamut of Ministry of Health and Family Welfare.


    Also Read: Dr Reddys Chairman Satish Reddy named as New President of Indian Pharmaceutical Alliance

    AmgencancerCDSCOCDSCO committeeDCGIDesosumabDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDrug Controller General of IndiamyelomaSECSubject expert committeeXgeva

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok